StockWireNews
(TPIA) Blazes Out Of The Opening Bell Up Approximately 25% Early, Requires Immediate Attention
February 14th
Greetings Readers,
TPIA is shooting up the charts early this morning and could be gaining steam.
With its early burst, TPIA is currently up approximately 35% and it may just be the start.
Over at Barchart, the site is reporting several triggered technicals for TPIA across the short, medium, and long term.
Those include its:
Short Term Indicators
- 20 - 50 Day MACD Oscillator
- 20 - 100 Day MACD Oscillator
Medium Term Indicators
- 50 Day Moving Average
- 50 - 100 Day MACD Oscillator
- 50 - 150 Day MACD Oscillator
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
With an early high of $3.50 and these multiple triggered technicals already appearing bullish, it may be just a matter of time until the website shows us even more triggered technicals.
If you haven't done so yet, check out my initial report below.
With a potential merger nearing, it could be a true game-changer for this currently under-the-radar company.
-----
Since I've got your attention, I've uncovered a breakout idea that could be on the verge of exploding based on 5 key potential catalysts.
Those include, the signing of an LOI to explore a game-changing merger, a huge "Sandbox" purchase, and a low float among others.
Psych-e-delics ("PSYCHs") have long brought to mind fantastical ideas and developments.
Magic mush-rooms, Woodstock and L-S-D-induced hallucinations are among just a few.
But some corners of the healthcare industry have started exploring PSYCHs for the treatment of certain behavioral health conditions.
One of the biggest is the fight against depression.
As proponents seek to change the negative perception long tied to PSYCH substances, a cottage industry of startups has emerged in the young market.
The PSYCH wellness industry has been bolstered, in part, by behavioral health clinicians and patients becoming more willing to try new alternative treatments like psi-lo-cybin.
The space is also likely getting a lift from the pandemic, which has caused stress, anxiety and depression to become more prevalent and severe, consequently leading to an uptick in demand for behavioral health services.
Due to those factors, the global PSYCH dr-ug market is expected to grow to over $69Bn by 2025, according to the financial data site Research and Markets.
The figure far surpasses a previous estimate from Research and Markets, which in December projected the industry would grow to a value of $10.75Bn by 2027.
To put it bluntly, PSYCHs present an opportunity to potentially bolster providers’ treatment toolbox and help patients for whom current psychiatric medications have failed.
For these reasons and more that I'll highlight in this report, I've been tracking a specific company closely.
Based on recent corporate actions, future market potential, and several possible catalysts, there is only one biopharma profile to have on your radar for Monday, February 14th:
*Mycotopia Therapies Inc. (TPIA)*
Mycotopia Therapies focuses on helping individuals heal and reclaim their lives. Their journey of healing is an understanding of the causes and works to mental wellness through PSYCH enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. PSYCH therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years.
And right now, based on these 5 potential catalysts, TPIA requires immediate attention:
#1. - Company Signs LOI To Explore Merger That Could Provide Unreal Potential
#2. - Huge Purchase In The Sandbox Could Become Company Defining
#3. - Low Float Profile
#4. - Health Reversal Potential Based On Oversold Leaning Technicals
#5. - Company Announces Plans To Develop Sublingual Tablet
So let's dive in quickly...
#1. TPIA Potentially Breakout Catalyst - Company Signs LOI To Explore Merger That Could Provide Unreal Potential
Mycotopia and Ei.Ventures sign LOI to Explore Merger and Formation of PSLY.COM, a $360Mn Transaction, And Will Apply To List Shares On NASDAQ
Post-acquisition company would focus on Ei.Ventures’ flagship product Psilly, a whole-plant Botanical Psi-lo-cybin-based formulation, which is currently in the pre-clinical phase
MIAMI, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical PSYCHs, announced today it has entered into a letter of intent regarding a potential acquisition of botanical psi-lo-cybin pioneer, Ei.Ventures. When a definitive agreement is reached, the combined companies intend to pool their resources to develop regulatory approved, plant-derived, psychoactive therapeutic treatment options and non-psychoactive nutritional supplements and related products that address global mental healthcare needs. The parties expect any transaction would close in the first quarter of 2022. At closing David Nikzad and Jason A. Hobson would be appointed as officers and directors of the Company and the Company would change its name to PSLY.COM, to better reflect the Company’s business moving forward. The Company plans to use PSLY as its trading symbol.
Ei.Ventures’ flagship botanical psi-lo-cybin-based formulation Psilly is a whole-plant botanical psi-lo-cybin-based formulation, which is currently in the pre-clinical phase. The goal of the combined companies would be to complete pre-clinical and phase 1 trials and launch therapeutic Psilly into jurisdictions where psi-lo-cybin is legal. Psilly is a whole plant and fungi botanical formulation. Ei.Ventures has pioneered using the whole plant and fungi in its botanical formulations, which has the potential to create the “Entourage Effect.” Researchers suggest the Entourage Effect could be key to Psi-lo-cybin’s healing properties. The Entourage Effect is a synergistic interaction between two or more different molecules found within the same plant. Similar to how various strains of cann-a-bis has different effects on the end-user, the same effect is now believed to hold true with Psi-lo-cybin mush-rooms.
Mycotopia Therapies is focused on the research, development, and commercialization of novel therapeutics based on naturally-derived psi-lo-cybin. Performing most of its research in Jamaica, where psi-lo-cybin is legal, Mycotopia Therapies is focused on mush-room and PSYCH opportunities. Mycotopia Therapies is currently working with one of the largest cann-a-bis labs in the Netherlands to develop PSYCHs to jointly license certain molecules to be used in PSYCH medicine. Mycotopia Therapies also plans to open psy-lo-cibin and ket-a-mine clinics in Jamaica under the direction of a licensed clinical psychiatrist. Mycotopia Therapies’ psy-lo-cibin and ket-a-mine clinic will be designed to make the most peaceful and serene setting possible to give patients an ideal situation for PSYCH therapies. The primary focus of each clinic will be to help patients heal and reclaim their life under the direction of a licensed clinical psychiatrist.
PSLY.COM, the combined company, would focus its efforts on developing fungi and plant based Botanical PSYCH API and Therapeutics instead of single molecule synthetic drugs with the belief that research will continue to confirm the importance of a synergistic approach. This would set PSLY.COM apart from virtually every other company in the space developing synthetic versions of Psi-lo-cybin. Ei.Ventures holds the IP for the extraction process of three botanical potential API compounds, Psi-lo-cybin, DMT and MDMA. PSLY.COM plans to further develop this API and file a Dr-ug Master File with the FDA, which will provide the opportunity to potentially sell the API to other organizations while protecting its IP.
David Nikzad, Founder and Chairman of Ei.Ventures, said, “I am excited by the amount of wisdom these two companies could bring together. Everyone in these companies has a background in public markets, a decade plus in cann-a-bis, and lawyers that have been involved in cann-a-bis legislation, as well as start-ups, and heavily compliance-oriented businesses. We were the first to work on legally-compliant C-B-D products, and we were the first to work on a commercial Ayurvedic spa in the US built around plant medicine. Between Benny, Jason and myself we’ve invested in more than 100 companies. This is not our first rodeo. That’s what makes this a real Olympic team, ‘A’ players only.”
Jason Hobson, Co-Founder and COO of Ei.Ventures, said, "With this deal we would be moving our growth forward by a huge leap, allowing us to accelerate our timeline of research in natural psi-lo-cybin delivery, like our recently announced transdermal delivery initiative. Mycotopia Therapies’ focus on mental health solutions is in alignment with our goals and we look forward to helping people move toward mental wellness with the amazing team at Mycotopia Therapies."
Ben Kaplan, CEO of Mycotopia Therapies said, "Psi-lo-cybin and other PSYCH medicines have tremendous potential to improve the mental health of many people who have given up hope. Our passion has been focused on how Psi-lo-cybin and other PSYCH medicines are changing the lives of many individuals struggling with anxiety, depression, PTSD, o-pioid use disorder and other harmful addictions." Mr. Kaplan continued, "Joining forces with Ei.Ventures presents a unique solution with the potential to accelerate our results. We are excited to work with the Ei.Ventures team in an attempt to enhance value for our shareholders."
Read the full article here.
-----
#2. TPIA Potentially Breakout Catalyst - Huge Purchase In The Sandbox Could Become Company Defining
Mycotopia Therapies Announces Ei.Ventures Acquires 12x12 Estate in The Sandbox in Anticipation of PSLY.COM Launch Post-Merger with Mycotopia Therapies in Q1 2022
Purchase to be named PSLY.COM represents the third largest land sale in the Metaverse valued at $2.2Mn
MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical PSYCHs, announced today Ei.Ventures has acquired a 12x 12 estate in The Sandbox, a virtual world where players can build, own, and monetize their gaming experiences on the Eth-er-eum block-chain. This purchase represents the third largest land sale in the Metaverse, and is valued at $2.2Mn. The land will be called PSLY.COM, the name of the soon to be merged company of Ei.Ventures with Mycotopia Therapies. The transaction was the subject of a January 5, 2022 article in Forbes by A.J. Herrington titled Startup Plans PSYCH Trips In The Metaverse With Sandbox Virtual Land Deal.
After only a week on the platform, Ei.Ventures and Orthogonal Thinker CEO David Nikzad were ready to invest in a legacy project for the combined companies’ vision of PSYCH therapy and move into the Metaverse over the next 36 months, noting, “The combination of our tech, cann-a-bis, PYSCHs, outer space, and cryp-to related holdings will all be utilizing this exciting space. We are very excited to invite all of our portfolio companies and investors to be part of something very special."
Ei.Ventures now owns 144 pieces of Sandbox land that make up this 12 x 12 estate. Their neighbors include noted companies like Axie Infinity, SANDBOX, Binance and many others. PSLY.COM is now right in the middle of these disruptive giants.
Nikzad adds, “As I remember my early days as an investor going to Y Combinator, it was about looking at things that were 10B disruptive. Health and Wellness is a Tn-dollar market. As we’ve now gone through CVD and are still in the craziness of it, these technologies will become much more important as communications and how financial transactions are handled is changing,” and ends with thanks to “Block-chain(dot)com, MetaMask, NFTTRADER and all the individuals and teams, including Ei’s co-founders, that came together to execute this transaction.”
Ben Kaplan, CEO of Mycotopia Therapies said, “Virtual land sales on the Sandbox have exploded recently and total sales between 2019 and today amount to $211Mn, while the 'sand' cryp-to-currency is up more than 9,000% in the last year. Block-chain technology allows users to own the content they create in The Sandbox and mint it onto non-fungible tokens, or NFTs.” Mr. Kaplan continued, “Since complex networks exist in the Metaverse without any one entity having overall control, the amount of land in The Sandbox is finite. As we work toward closing our merger with Ei.Ventures, I believe this in-vest-ment in the Metaverse will prove to be very beneficial for PSLY.COM shareholders.”
[...]
Read the full article here.
-----
#3. TPIA Potentially Breakout Catalyst - Low Float Profile
According to the OTC Markets' website, TPIA has a low float.
The website reports this profile to have approximately 1.09Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts could help spark a vertical move in the short-term.
-----
#4. TPIA Potentially Breakout Catalyst - Health Reversal Potential Based On Oversold Leaning Technicals
As of close on Thursday, Barchart was reporting this profile to have several oversold leaning technicals.
These technicals could be signaling a healthy reversal in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Now, here are some key technicals (as of close Thursday) that could signal TPIA to be leaning oversold and on the verge of a potential reversal.
- 9-Day Relative Strength Index: 37.28%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 10.12%
- 14-Day Williams %R: 89.88%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
-----
#5. TPIA Potentially Breakout Catalyst - Company Announces Plans To Develop Sublingual Tablet
Mycotopia Therapies Announces Plan to Develop PSYCH Sublingual Tablet to Help Treat Depression
MIAMI, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical PSYCHs, announced today it has initiated plans for a psi-lo-cybin-based pharmaceutical program by entering into an agreement to form a 50/50 joint venture (the “Joint Venture”) with Agile Pharmaceutical Solutions to develop novel oral dosage forms of psi-lo-cybin in the form of a PSYCH sublingual tablet. The two parties plan to attain a Health Canada License for PSYCHs to obtain and test PSYCH raw material, for the purpose of creating the psi-lo-cybin-based, sublingual tablet to take to market.
Mycotopia Therapies and Agile Pharmaceutical Solutions plan to conduct oversight and development of the tablet in Jamaica and explore the possibility of partnering with Havn Life Sciences (CSE: HAVN) (OTC Pink: HAVLF) in Jamaica for raw materials and developing the tablet. In August Mycotopia Therapies, Inc. announced it had entered into a Psi-lo-cybin Supply Agreement with Havn Life Sciences to purchase naturally-derived psi-lo-cybin. Should the Joint Venture be granted Health Canada PSYCHs License, the terms of the agreement call for moving the operations to Canada for final testing to prove efficacy of the tablet.
Sublingual tablets are placed under the tongue. There, they dissolve rapidly beneath the tongue and enter directly into the tiny blood vessels beneath. Via these capillaries, sublingual dr-ugs can enter the bloodstream much more quickly than oral medications. Sublingual tablets dispense the full amount of medication directly into the bloodstream without experiencing liver metabolism. As a result, physicians can prescribe smaller dosages that are guaranteed to reach their intended target. Because a sublingual dose of medicine is administered and absorbed under the tongue, it bypasses the stomach and its contents on its way to the bloodstream. As a result, sublingual drugs do not interact with foods and other medications before absorption. The dosage does not cause or experience interference by other medications and does not cause the gastrointestinal irritation of some oral medications. Individuals who have trouble swallowing or have pill aversions sometimes avoid taking medications due to the stress caused by oral medications. Sublingual versions of the same medicines can make taking prescription medications much easier, as the tablet does not need to be swallowed.
[...]
Ben Kaplan, CEO of Mycotopia Therapies said, "This opportunity to develop a PSYCH sublingual tablet using the intellectual property of Agile Pharmaceutical Solutions is a tremendous opportunity for Mycotopia Therapies. The real opportunity, however, is derived from our two companies working together toward the common goal of revolutionizing how mental illness is treated. The sublingual administration presents an opportunity to possibly set a new standard for PSYCH assisted therapy.”
Read the full article here.
-----
TPIA Recap - 5 Potential Breakout Catalysts To Know Now
#1. - Company Signs LOI To Explore Merger That Could Provide Unreal Potential
#2. - Huge Purchase In The Sandbox Could Become Company Defining
#3. - Low Float Profile
#4. - Health Reversal Potential Based On Oversold Leaning Technicals
#5. - Company Announces Plans To Develop Sublingual Tablet
-----
Coverage is officially initiated on TPIA. When you have a sec, do this:
